Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Anthony Child

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
Blood|October 18, 2002
Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantationAndy C Rawstron, Faith E Davies, Ranjit DasGupta, et al.
JAMA Oncology|September 16, 2016
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysisNikhil C Munshi, Herve Avet-Loiseau, Andy C Rawstron, et al.
British Journal of Haematology|June 3, 2017
Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain testsJennifer L J Heaney, John P Campbell, Anne E Griffin, et al.
Blood|April 14, 2012
Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX TrialGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
British Journal of Cancer|July 21, 2017
Active multiple myeloma suppresses and typically eliminates coexisting MGUSJohn P Campbell, Jennifer L J Heaney, Sankalp Pandya, et al.
British Journal of Haematology|July 10, 2018
Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised studyKara-Louise Royle, Walter M Gregory, David A Cairns, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2013
Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatmentGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Leukemia|June 22, 2018
Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trialsJennifer L J Heaney, John P Campbell, Gulnaz Iqbal, et al.
Blood|February 4, 2015
Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reductionAndy C Rawstron, Walter M Gregory, Ruth M de Tute, et al.
Blood|June 7, 2003
Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myelomaRanjit K Dasgupta, Peter J Adamson, Faith E Davies, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Blood|October 18, 2002
Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantationAndy C Rawstron, Faith E Davies, Ranjit DasGupta, et al.
JAMA Oncology|September 16, 2016
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysisNikhil C Munshi, Herve Avet-Loiseau, Andy C Rawstron, et al.
British Journal of Haematology|June 3, 2017
Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain testsJennifer L J Heaney, John P Campbell, Anne E Griffin, et al.
Blood|April 14, 2012
Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX TrialGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
British Journal of Cancer|July 21, 2017
Active multiple myeloma suppresses and typically eliminates coexisting MGUSJohn P Campbell, Jennifer L J Heaney, Sankalp Pandya, et al.
British Journal of Haematology|July 10, 2018
Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised studyKara-Louise Royle, Walter M Gregory, David A Cairns, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2013
Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatmentGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Leukemia|June 22, 2018
Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trialsJennifer L J Heaney, John P Campbell, Gulnaz Iqbal, et al.
Blood|February 4, 2015
Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reductionAndy C Rawstron, Walter M Gregory, Ruth M de Tute, et al.
Blood|June 7, 2003
Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myelomaRanjit K Dasgupta, Peter J Adamson, Faith E Davies, et al.
Pageof 5